InsiderTrades

Form 4 for HRTX HERON THERAPEUTICS, INC. /DE/

Accepted 2022-10-17 00:00:00 ET · period of report 2022-10-13 · accession 0001209191-22-053835 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2022-10-17 2022-10-13 HRTX Quart Barry D CEO, Dir M - OptEx — +19.8K 167.0K +13% —
D 2022-10-17 2022-10-13 HRTX Quart Barry D CEO, Dir F - Tax $3.76 -5,219 161.8K -3% -$19.6K
DM 2022-10-17 2022-10-13 HRTX Quart Barry D CEO, Dir M - OptEx $0.00 -19.8K 130.9K -13% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-10-13 M A 3,646 — 150,883 D — — (F1) Restricted stock units convert into common stock on a one-for-one basis.
2 Common Common Stock 2022-10-13 F D 5,219 $3.76 161,786 D — — (F2) Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.
3 Common Common Stock 2022-10-13 M A 16,122 — 167,005 D — — (F1) Restricted stock units convert into common stock on a one-for-one basis.
4 Derivative Restricted Stock Units 2022-10-13 M D 3,646 $0.00 29,166 D — · — to — 3,646 Common Stock (F1) Restricted stock units convert into common stock on a one-for-one basis. (F3) The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).
5 Derivative Restricted Stock Units 2022-10-13 M D 16,122 $0.00 130,929 D — · — to — 16,122 Common Stock (F1) Restricted stock units convert into common stock on a one-for-one basis. (F4) The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).